RCT: Subcutaneous REGEN-COV antibody combination prevented symptomatic Covid-19 infection in previously uninfected household contacts of infected persons.

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 – New England Journal of Medicine

Related:

RCT: Bamlanivimab plus Etesevimab reduce mortality and hospitalization in ambulatory patients with early Covid-19 (within 3 days of a positive test) who are at risk for clinical deterioration (i.e., older people, obese, diabetics, immunocompromised, with CV disease).

[Preprint] RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalized COVID-19 patients who have not mounted their own immune response.

Commentary on Twitter

Subcutaneous REGEN-COV prevented symptomatic #COVID19 and asymptomatic #SARSCoV2 infection in previously uninfected household contacts. https://t.co/rRNFTjS9hX pic.twitter.com/B7qXeyWKUb

— NEJM (@NEJM) August 4, 2021